使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Intuitive Surgical quarter-two 2015 earnings release call. (Operator Instructions). As a reminder, this conference is being recorded.
各位女士、先生,感謝您稍候。歡迎參加直覺外科(Intuitive Surgical)2015 年第二季財報發布電話會議。(接線員指示)。提醒您,本次會議將被錄音。
I would now like to turn the conference over to our host, Calvin Darling, Senior Director of Finance for Intuitive Surgical. Please go ahead.
現在我想把會議交給我們的主持人——直覺外科財務資深總監 Calvin Darling。請開始。
Calvin Darling - Director, FP&A and IR
Calvin Darling - Director, FP&A and IR
Thank you. Good afternoon and welcome to Intuitive Surgical's second-quarter earnings conference call. With me today, we have Gary Guthart, our President and CEO; and Marshall Mohr, our Chief Financial Officer. Note that Patrick Clingan, who has participated on these calls in recent quarters, will not be with us on the call today due to minor illness. We expect him back in the office next week.
謝謝。各位下午好,歡迎參加直覺外科第二季財報電話會議。今天與我一同出席的有:總裁暨執行長 Gary Guthart,以及財務長 Marshall Mohr。請注意,近幾季曾參與本電話會議的 Patrick Clingan,因輕微疾病今天將不會參與。我們預期他下週會回到辦公室。
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the Company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 5, 2015, and 10-Q, filed on April 22, 2015. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.
在開始之前,我想提醒各位,今天電話會議中提及的評論可能被視為包含前瞻性陳述。由於某些風險與不確定性,實際結果可能與明示或暗示的內容有重大差異。這些風險與不確定性已在本公司向美國證券交易委員會(SEC)提交的文件中詳細說明,包括我們於 2015 年 2 月 5 日提交的最新 Form 10-K,以及於 2015 年 4 月 22 日提交的 10-Q。這些文件可透過我們的網站或 SEC 的 EDGAR 資料庫查閱。提醒潛在投資人勿過度依賴此類前瞻性陳述。
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com, on the audio archive section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website.
請注意,本次電話會議將可於我們網站 intuitivesurgical.com 的投資人關係頁面下之音訊存檔區提供音訊重播。此外,今天的新聞稿與補充財務資料表亦已張貼於我們網站。
Today's format will consist of providing you with highlights of our second-quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights; Marshall will provide a review of our second-quarter financial results; then I will discuss procedure and clinical highlights, and provide our updated financial outlook for 2015. And finally we will host a question-and-answer session.
今天的流程將先提供我們第二季業績重點(如今日稍早發布之新聞稿所述),接著進行問答。Gary 將介紹本季的業務與營運重點;Marshall 將回顧第二季財務結果;接著我將說明手術量與臨床重點,並提供我們更新後的 2015 年財務展望。最後我們將進行問答環節。
With that, I will turn it over to Gary.
接下來我把時間交給 Gary。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Thank you for joining us on the call for today. In the quarter, growth in procedures was healthy, maintaining the rate of growth we experienced in the first quarter and showing solid performance in several specialties and geographies. Our capital performance improved in the quarter, as did our margins.
感謝各位今天加入本次電話會議。本季手術量成長健康,維持第一季的成長速度,並在多個專科與地區展現穩健表現。本季我們的資本設備表現有所改善,毛利率亦有所提升。
Starting with procedures, year-over-year growth in the second quarter was just under 14% compared with Q2 of 2014. Utilization trends present last quarter continued, with strength in hernia repair, solid growth in colon and rectal resections, continued recovery in prostatectomy, and stable trends in hysterectomy.
先從手術量來看,第二季年增率略低於 14%,相較於 2014 年第二季。上季呈現的使用率趨勢延續,包括疝氣修補的強勁表現、結腸與直腸切除的穩健成長、前列腺切除術的持續復甦,以及子宮切除術趨勢穩定。
Growth in the use of our products was broad-based and included the US, Europe, and key markets in Asia. Procedures grew strongly in China, and growth was solid in Japan and Korea. Calvin will review procedure trends in greater detail later in the call.
我們產品的使用成長相當廣泛,涵蓋美國、歐洲以及亞洲的關鍵市場。中國手術量強勁成長,日本與韓國的成長亦穩健。Calvin 稍後將在會議中更詳細回顧手術量趨勢。
Turning to capital sales, we placed 118 systems in the quarter compared to 96 in the second quarter of 2014. The United States and Japan accounted for most of the growth in system placements year-over-year. We see interest across our product line, from our multi-quadrant Xi system to our Si system, with customers choosing the system that best fits their program's needs.
再看資本設備銷售,本季我們裝機 118 套系統,較 2014 年第二季的 96 套增加。美國與日本貢獻了大部分的年度系統裝機成長。我們看到市場對全產品線皆有興趣,從多象限的 Xi 系統到 Si 系統,客戶會選擇最符合其計畫需求的系統。
In Japan, clearance of the Xi system unlocked some system demand. And we sold 13 systems in the quarter compared with 5 a year earlier. Procedure growth in Japan remains healthy, given the current state of reimbursement. As we have said on prior calls, the growth of the market in Japan will be paced by continued progress on reimbursement.
在日本,Xi 系統獲准上市釋放了部分系統需求。本季我們在日本售出 13 套系統,較去年同期的 5 套增加。在目前的給付狀況下,日本的手術量成長仍然健康。如同我們在先前電話會議所說,日本市場的成長速度將取決於給付持續取得進展的步調。
Clinical investigators have submitted their partial nephrectomy data to MHLW for review, and ISI continues to work with key stakeholders in the reimbursement for additional procedures. We have no assurance of additional procedure reimbursement at this time.
臨床研究人員已將其部分腎切除術(partial nephrectomy)資料提交至日本厚生勞動省(MHLW)審查,而 ISI 也持續與關鍵利害關係人合作,推動更多手術項目的給付。目前我們無法保證會有額外手術項目獲得給付。
Turning to margins, our operating teams are focused on reducing product costs for our new products and we are managing our fixed expenses carefully. This quarter was a step in the right direction on gross margin, though an early one. We will continue to focus on improvements over the next several quarters. Marshall will take you through this and other financial performance in greater detail later in the call.
再看毛利率,我們的營運團隊專注於降低新產品的產品成本,並審慎管理固定費用。本季在毛利率方面朝正確方向邁進,儘管仍屬初步。未來幾季我們將持續聚焦改善。Marshall 稍後將更詳細說明此項及其他財務表現。
In summary, our operating performance for the second quarter is as follows. Procedures grew just under 14% over the second quarter of last year. We placed 118 da Vinci Surgical Systems, up from 96, in the second quarter of 2014. Total pro forma revenue for the quarter was $586 million, up 16% from the prior year, and up 20% year-over-year on a constant currency basis.
總結而言,我們第二季的營運表現如下。手術量較去年第二季成長略低於 14%。我們裝機 118 套達文西手術系統(da Vinci Surgical Systems),高於 2014 年第二季的 96 套。本季調整後(pro forma)總營收為 5.86 億美元,較去年同期成長 16%;以固定匯率計算,年增 20%。
Total pro forma instrument and accessory revenue increased to $297 million, up 13% over prior year. We generated pro forma operating profit of $228 million in the quarter compared with $196 million in the second quarter of 2014. And pro forma net income was $173 million compared to $140 million in Q2 of 2014.
本季調整後器械與配件(instrument and accessory)營收增至 2.97 億美元,較去年同期成長 13%。本季調整後營業利益為 2.28 億美元,較 2014 年第二季的 1.96 億美元增加。調整後淨利為 1.73 億美元,對比 2014 年第二季的 1.40 億美元。
In product development, we are rounding out our Xi system offering by launching additional EndoWrist instruments, integrating table motion with Xi, and developing Single-Site for Xi. In Europe in the second quarter, surgeons have performed the first clinical cases using integrated table motion with Xi, with enthusiastic feedback.
在產品開發方面,我們正透過推出更多 EndoWrist 器械、將手術台移動(table motion)與 Xi 整合,以及為 Xi 開發 Single-Site,來完善 Xi 系統的產品組合。在歐洲第二季,外科醫師已使用與 Xi 整合的手術台移動功能完成首批臨床案例,回饋相當熱烈。
We recently submitted our 510(k) for software that enables table motion with Xi. We anticipate filing our 510(k) for Xi Single-Site in the second half of the year.
我們近期已提交可啟用 Xi 手術台移動功能之軟體的 510(k) 申請。我們預期將於下半年提交 Xi Single-Site 的 510(k) 申請。
We have also broadened the roll-out of our white reload for our da Vinci Xi Stapler. Feedback on its utility has been positive. Additional Xi EndoWrist instruments have been released in the quarter, continuing to round out our instrument offering for Xi.
我們也擴大推出適用於達文西 Xi 吻合器(da Vinci Xi Stapler)的白色 reload。對其實用性的回饋為正面。本季亦發布了更多 Xi EndoWrist 器械,持續完善 Xi 的器械產品組合。
For da Vinci Sp, our dedicated single point of entry architecture, development is progressing with system integration and laboratory testing in progress.
至於 da Vinci Sp(我們專用的單一進入點架構),開發正持續推進,目前正在進行系統整合與實驗室測試。
Stepping back and looking at the business at the midway point of the year, we are focused on expanding the application of da Vinci in general surgery, particularly colorectal surgery in hernia repair; filling out our product line for da Vinci Xi and launching in key markets globally; developing our organizational capabilities in markets in Europe and Asia; improving our gross margins; and advancing our technologies to improve surgery.
回顧年度過半時的業務重點,我們聚焦於:擴大達文西在一般外科的應用,特別是大腸直腸手術與疝氣修補;完善達文西 Xi 的產品線並在全球關鍵市場推出;提升我們在歐洲與亞洲市場的組織能力;改善毛利率;以及推進技術以改善手術。
I will now turn the call over to Marshall, who will review our financial performance.
現在我把電話會議交給 Marshall,由他回顧我們的財務表現。
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
Thank you, Gary. I will be describing our results on a non-GAAP or pro forma basis, which excludes the impact of our prior-year Xi trade-in programs, legal claim accruals, stock-based compensation, amortization of purchased IP, and investment impairments. We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website so that there's no confusion.
謝謝你,Gary。我將以非 GAAP 或調整後(pro forma)基礎說明我們的結果,該基礎排除前一年度 Xi 換機方案、法律索賠準備、以股份為基礎之薪酬、外購智慧財產權(IP)攤銷,以及投資減損的影響。我們提供調整後資訊,是因為我們認為以調整後基礎更容易理解業務趨勢與營運結果。我也會在講稿稍後摘要說明我們的 GAAP 結果。我們已在網站上提供調整後結果與 GAAP 結果的調節表,以避免混淆。
Pro forma second-quarter revenue was $586 million, an increase of 16% compared with $507 million for the second quarter of 2014, and an increase of 10% compared with last quarter. Pro forma revenue for the second quarter of 2014 excludes net revenue associated with offers made in 2014 to trade out Si product for Xi product. All trade-out offers were either fulfilled or lapsed in 2014.
備考第二季營收為5.86億美元,較2014年第二季的5.07億美元成長16%,並較上一季成長10%。2014年第二季的備考營收不包含與2014年提出以Si產品換購Xi產品之優惠相關的淨營收。所有換購優惠均已於2014年履行完畢或到期失效。
Second-quarter procedures of approximately 162,000 grew nearly 14% compared with the second quarter of 2014, and approximately 8% compared with the first quarter of 2015.
第二季手術量約162,000例,較2014年第二季成長近14%,並較2015年第一季成長約8%。
Revenue highlights are as follows. Pro forma instrument and accessory revenue grew 13% compared with the second quarter of 2014, and increased 7% compared with the first quarter 2015. The increase relative to the prior year reflects procedure growth and customer buying patterns, partially offset by the impact of foreign exchange. The increase relative to the prior quarter primarily reflects procedure growth.
營收重點如下。備考器械與配件營收較2014年第二季成長13%,並較2015年第一季增加7%。相較前一年之增加反映手術量成長與客戶採購模式,部分被外匯影響所抵銷。相較前一季之增加主要反映手術量成長。
Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,830 per procedure, approximately the same as the second quarter of 2014, and similar to the approximately $1,840 last quarter.
每例手術實現之器械與配件營收(包含初始備貨訂單)約為每例1,830美元,與2014年第二季大致相同,亦與上一季約每例1,840美元相近。
Pro forma system revenue of $176 million increased 27% compared with the second quarter of 2014, and increased 25% compared with the first quarter of 2015. The increase relative to the prior year reflects increased unit sales, partially offset by the impact of foreign exchange. The increase compared with the first quarter primarily reflects increased unit sales.
備考系統營收為1.76億美元,較2014年第二季成長27%,並較2015年第一季成長25%。相較前一年之增加反映銷售台數增加,部分被外匯影響所抵銷。相較第一季之增加主要反映銷售台數增加。
118 systems were placed in the second quarter compared with 96 systems in the second quarter of 2014, and 99 systems last quarter. 64% of the systems placed in the second quarter were Xis compared with 52% in the second quarter of 2014, and 76% in the first quarter of 2015. We sold more Sis in the quarter than the previous quarter, reflecting 7 Si system sales under a contract with the Department of Defense, and 8 Si system sales in Japan. We expect the mix of Xi to Si product to fluctuate quarter-to-quarter.
第二季裝機118套系統,較2014年第二季的96套增加,亦高於上一季的99套。第二季裝機系統中,Xi占64%,相較2014年第二季的52%,以及2015年第一季的76%。本季Si銷量高於前一季,反映在與國防部合約下售出7套Si系統,以及在日本售出8套Si系統。我們預期Xi與Si產品的組合占比將隨季度而波動。
Service revenue of $113 million increased 6% year-over-year and decreased $1 million compared with the first quarter of 2015. The year-over-year increase reflects the increase in our installed base. The decrease compared with the first quarter reflects the timing of service contract renewals and changes in foreign exchange rates, partially offset by an increase in our installed base.
服務營收為1.13億美元,年增6%,並較2015年第一季減少100萬美元。年增主要反映我們裝機基數增加。相較第一季之減少反映服務合約續約時點及外匯匯率變動,部分被裝機基數增加所抵銷。
Globally, our system ASP of $1.5 million was approximately the same as the second quarter of last year, and increased relative to the first-quarter ASP of $1.48 million. Relative to the second quarter of 2014, higher ASPs were primarily associated with higher mix of Xis, offset by the impact of the strengthened dollar. The increase in ASPs relative to last quarter reflect geographic mix and lower trade-in activity. ASPs will fluctuate on a geographic and product mix, trade-in volume, and changes in foreign exchange rates.
全球而言,我們系統平均售價(ASP)為150萬美元,與去年第二季大致相同,並較第一季ASP的148萬美元上升。相較2014年第二季,較高的ASP主要與Xi占比較高相關,但被美元走強的影響所抵銷。相較上一季ASP的上升反映地區組合以及較低的以舊換新活動。ASP將因地區與產品組合、以舊換新量,以及外匯匯率變動而波動。
Hospitals financed approximately 21% of the systems placed in the second quarter, up from 14% last quarter. We directly financed 12 systems, of which five were structured as operating leases. Several customers bought out previously leased systems in the quarter. Although revenue associated with the buyouts are included in total revenue, we have excluded this revenue from the computation of system ASPs. We have also excluded these buyouts from the system placement number.
醫院為第二季裝機系統中約21%提供融資,高於上一季的14%。我們直接融資12套系統,其中5套採營業租賃架構。本季有數位客戶買斷先前租賃的系統。雖然與買斷相關的營收已納入總營收,我們已將該等營收自系統ASP的計算中排除。我們亦將該等買斷自系統裝機數中排除。
In the US, we placed 72 systems in the second quarter, compared with 61 systems in the second quarter of 2014, and 63 systems in the first quarter of 2015. As previously noted, second-quarter system placements in the US included seven systems sold under our Department of Defense contract. In general, the increase in system placements relative to the prior year reflect growth in procedures and market acceptance of the Xi system.
在美國,我們第二季裝機72套系統,較2014年第二季的61套增加,亦高於2015年第一季的63套。如先前所述,美國第二季系統裝機包含在國防部合約下售出的7套系統。整體而言,相較前一年系統裝機增加反映手術量成長以及市場對Xi系統的接受度提升。
Outside of the US, results were as follows. Second-quarter pro forma revenue outside the US of $168 million grew 25% compared with $135 million for the second quarter of 2014, and grew 12% compared with $150 million last quarter.
美國以外地區的結果如下。美國以外地區第二季備考營收為1.68億美元,較2014年第二季的1.35億美元成長25%,並較上一季的1.50億美元成長12%。
The increase compared with the previous year reflects higher Japan system revenue, higher instrument and accessory revenue reflecting procedure growth, partially offset by foreign exchange. The increase compared with last quarter reflects higher Japan systems placements, geographic mix of system placement, and procedure growth.
相較前一年之增加反映日本系統營收較高,以及因手術量成長帶動的器械與配件營收較高,部分被外匯影響所抵銷。相較上一季之增加反映日本系統裝機較高、系統裝機的地區組合,以及手術量成長。
Outside the US, we placed 46 systems in the second quarter compared with 35 in the second quarter of 2014, and 36 systems last quarter. O-US system placements reflect 13 systems into Japan this quarter compared with five systems in the second quarter of 2014, and one last quarter. We obtained Xi approval in Japan in late March, and five of the systems sold this quarter were Xi systems.
在美國以外地區,我們第二季裝機46套系統,較2014年第二季的35套增加,亦高於上一季的36套。本季美國以外(O-US)系統裝機包含在日本裝機13套,較2014年第二季的5套增加,亦高於上一季的1套。我們於3月下旬取得Xi在日本的核准,本季售出的系統中有5套為Xi系統。
European system placements grew to 22 systems this quarter compared with 19 last year and 18 last quarter. We placed no systems into China this quarter compared with one in the second quarter of 2014, and eight last quarter. As we have indicated in the past, and consistent with our history, system placements in our O-US markets will fluctuate quarter-to-quarter.
歐洲系統裝機本季增至22套,較去年19套及上一季18套增加。本季我們未在中國裝機,較2014年第二季的1套,以及上一季的8套為少。如我們過去所指出且與歷史一致,我們在美國以外市場的系統裝機將隨季度而波動。
Moving on to the remainder of the P&L, pro forma gross margin in the second quarter of 2015 was 68% compared with 69.2% for the second quarter of 2014, and 65.6% for the first quarter of 2015. The decline in gross margins relative to the second quarter of 2014 is primarily attributable to foreign exchange and a higher mix of newer products, including Xi and stapling. The sequential improvement in gross margin is primarily attributable to the completion of activities that resulted in one-time charges in the first quarter, and cost of sales efficiency gains.
接著看損益表其餘項目,2015年第二季備考毛利率為68%,相較2014年第二季的69.2%,以及2015年第一季的65.6%。相較2014年第二季毛利率下滑主要歸因於外匯,以及較高比例的新產品組合(包括Xi與縫合器)。毛利率的季比改善主要歸因於完成了在第一季造成一次性費用的相關活動,以及銷貨成本效率提升。
In 2014 we recorded pre-tax charges of approximately $82 million, representing the estimated cost of settling a number of product liability legal claims under a tolling agreement. During 2015, we have refined our estimate of the overall cost of settling claims, and recorded additional charges of approximately $7 million in each of the first and second quarters. These charges are excluded from our pro forma results and are included in our GAAP results. We will continue to refine our estimates as we proceed through the negotiation process.
2014年我們認列約8,200萬美元的稅前費用,代表在一項中止時效協議(tolling agreement)下,和解多起產品責任法律索賠的估計成本。2015年期間,我們已精進對整體索賠和解成本的估計,並於第一季與第二季各額外認列約700萬美元費用。這些費用已自我們的備考結果中排除,並納入我們的GAAP結果。隨著協商程序推進,我們將持續精進我們的估計。
Pro forma operating expenses -- which exclude the reserves for legal claims, stock compensation expense, and amortization of purchased IP -- increased 10% compared with the second quarter of 2014, and increased 4% compared with last quarter. The year-over-year increase of pro forma operating expenses primarily reflects headcount additions and higher incentive compensation.
備考營業費用——不包含法律索賠準備、股票酬勞費用,以及購買之智慧財產權(IP)攤銷——較2014年第二季增加10%,並較上一季增加4%。備考營業費用的年增主要反映人員編制增加以及較高的獎勵性薪酬。
Our pro forma effective tax rate for the second quarter was 25.6% compared with an effective tax rate of 29.8% for the second quarter of 2014, and 28.9% last quarter. The effective tax rate for the second quarter of 2015 benefited from approximately $8 million, or the equivalent of $0.21 per share of discrete items, including the release of reserves specific to tax years where we recently completed audits. Our tax rate will fluctuate with changes in the mix of US and O-US income, and will not reflect a federal research and development credit, unless such credit is reinstated.
我們第二季的備考有效稅率為25.6%,相較於2014年第二季的有效稅率29.8%,以及上一季的28.9%。2015年第二季的有效稅率受惠於約800萬美元(相當於每股0.21美元)的離散項目影響,其中包括釋放與我們近期完成稽核之特定稅務年度相關的準備金。我們的稅率將隨美國與非美國(O-US)所得組合的變化而波動,且除非聯邦研發抵減(research and development credit)恢復,否則不會反映該抵減。
Our pro forma net income was $173 million or $4.57 per share, compared with $140 million or $3.73 per share for the second quarter of 2014, and $135 million or $3.57 per share for the first quarter of 2015. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends.
我們的備考淨利為1.73億美元(每股4.57美元),相較於2014年第二季的1.40億美元(每股3.73美元),以及2015年第一季的1.35億美元(每股3.57美元)。如我先前所述,備考獲利能更容易比較我們的財務結果與業務趨勢。
I will now summarize our GAAP results.
我現在將摘要說明我們的GAAP結果。
GAAP revenue was $586 million for the second quarter of 2015 compared with $512 million for the second quarter of 2014, and $532 million for the first quarter of 2015. GAAP net income was $135 million or $3.56 per share for the second quarter of 2015, compared with $104 million or $2.77 per share for the second quarter of 2014, and $97 million or $2.57 per share for the first quarter of 2015.
2015年第二季GAAP營收為5.86億美元,相較於2014年第二季的5.12億美元,以及2015年第一季的5.32億美元。2015年第二季GAAP淨利為1.35億美元(每股3.56美元),相較於2014年第二季的1.04億美元(每股2.77美元),以及2015年第一季的9,700萬美元(每股2.57美元)。
We ended the quarter with cash and investments of $2.9 billion, up from $2.7 billion as of March 31, 2015. The increase was primarily driven by cash generated by operations and proceeds from stock option exercises, partially offset by stock buybacks. During the quarter, we repurchased approximately 100,000 shares for $49 million at an average purchase price of $494 per share.
本季結束時,我們的現金與投資為29億美元,高於截至2015年3月31日的27億美元。增加主要來自營運產生的現金及員工股票選擇權行使所得款項,部分被庫藏股回購所抵銷。本季我們以平均每股494美元的價格回購約10萬股,金額為4,900萬美元。
And with that, I'd like to turn it over to Calvin, who will go over our procedure and clinical highlights, and provide 2015 financial guidance.
接下來,我想把時間交給Calvin,他將說明我們的手術量與臨床重點,並提供2015年的財務指引。
Calvin Darling - Director, FP&A and IR
Calvin Darling - Director, FP&A and IR
Thanks, Marshall. Let me begin with a review of our procedure results. As mentioned earlier, total second-quarter year-over-year procedures grew just below 14%, with US procedures growing approximately 10%, and international procedures growing approximately 27%.
謝謝,Marshall。我先從回顧我們的手術量結果開始。如先前提到,第二季手術量年增率略低於14%,其中美國手術量約成長10%,國際手術量約成長27%。
In the US, trends observed during the first quarter largely continued through the second quarter. In urology, growth in da Vinci Prostatectomy and kidney cancer procedures continued at a similar rate as the first quarter. We continue to believe that our prostatectomy volumes have been tracking to the broader US prostate surgery market.
在美國,第一季觀察到的趨勢大致延續到第二季。在泌尿科方面,達文西前列腺切除術與腎癌手術的成長,與第一季相近。我們仍然認為,我們的前列腺切除術量一直與更廣泛的美國前列腺手術市場同步。
In US gynecology, procedures were flat year-over-year, with growth in malignant and complex hysterectomy offset by declines in benign procedures. In recent quarters, an increasing proportion of total hysterectomy procedures have been performed by gynecologic oncologists.
在美國婦科方面,手術量年比持平;惡性與複雜子宮切除術的成長,被良性手術的下滑所抵銷。近幾季,總子宮切除術中由婦科腫瘤科醫師執行的比例持續上升。
During the second quarter, general surgery remained the primary contributor to US growth, with robust growth in hernia repair and solid contribution from colorectal procedures being partially offset by continued declines in cholecystectomies.
第二季期間,一般外科仍是美國成長的主要貢獻來源;疝氣修補手術強勁成長,結直腸手術亦有穩健貢獻,但部分被膽囊切除術持續下滑所抵銷。
During the first half of 2015, ventral and inguinal hernia repair contributed the majority of the increase in US general surgery procedures. The contribution to first-half US growth from mature procedures in highly penetrated markets such as da Vinci Prostatectomy and da Vinci Malignant and complex hysterectomy, has exceeded our expectations. In the second half of 2015, growth in da Vinci Prostatectomy is likely to slow as we anniversary into higher prior-year growth rates.
2015年上半年,腹壁疝氣與腹股溝疝氣修補手術貢獻了美國一般外科手術量增加的大部分。在達文西前列腺切除術,以及達文西惡性與複雜子宮切除術等高度滲透市場中的成熟術式,對美國上半年成長的貢獻超出我們的預期。2015年下半年,隨著我們進入去年同期較高的成長基期,達文西前列腺切除術的成長可能放緩。
Looking abroad, during the second quarter, international procedure growth was led by a modest acceleration in the global adoption of da Vinci Prostatectomy, with solid contributions from kidney procedures, malignant hysterectomies, and colorectal resections. During the first half of 2015, growth in international da Vinci Prostatectomy was approximately 20%.
放眼海外,第二季國際手術量成長主要由全球採用達文西前列腺切除術的溫和加速所帶動;腎臟手術、惡性子宮切除術與結直腸切除亦有穩健貢獻。2015年上半年,國際達文西前列腺切除術成長約20%。
Let me take a few moments to provide a bit more color around China. Over the past year, we have sold 20 systems under tenders from among 38 civilian hospitals authorized by the government to acquire a da Vinci system. Procedure adoption has been broad-based in urologic, gynecologic, general, and thoracic procedures. While we are encouraged by these developments, future system placements are dependent on completion of the central purchasing tender under the current authorization, which is set to expire at the end of 2015. It is not certain whether the tender process will be completed or when future governmental authorizations and approvals may enable system placements in 2016 and beyond. Procedure growth rates are likely to be governed by the timing of additional system placements.
我花幾分鐘補充一些關於中國的情況。過去一年,我們在政府授權可採購達文西系統的38家民用醫院中,透過招標售出20套系統。手術採用面向廣泛,涵蓋泌尿科、婦科、一般外科與胸腔手術。雖然我們對這些進展感到鼓舞,但未來系統裝機仍取決於在現行授權下完成中央採購招標流程,而該授權預計於2015年底到期。目前尚不確定招標流程是否會完成,或未來政府授權與核准將於何時使我們能在2016年及之後進行系統裝機。手術量成長率很可能將受額外系統裝機時點所左右。
Moving on to clinical and economic validation. A recent publication from Saarlandes University by Professor Stockle and team evaluated the cost-effectiveness of da Vinci Prostatectomy compared to open prostatectomy from a German payer perspective in a 1,400-patient study, partially supported by Intuitive.
接著談臨床與經濟效益驗證。薩爾蘭大學(Saarlandes University)Stockle教授及其團隊近期發表的研究,在一項1,400名病患的研究中,從德國支付方角度評估達文西前列腺切除術相較於開放式前列腺切除術的成本效益;該研究部分由Intuitive支持。
From a clinical perspective, the robotic patient population showed fewer positive surgical margins and required fewer intraoperative transfusions, with a reduction in hospitalization of approximately 6 days.
從臨床角度來看,機器人手術病患族群呈現較少的陽性切緣,且術中輸血需求較低,住院天數約減少6天。
In the economic analysis, the study showed that the robotic patients were roughly EUR3,000 per patient less expensive, as measured by the period from the date of surgery to two years post-operation. The authors concluded that the improved clinical outcomes led to the reduction in postoperative costs.
在經濟分析方面,研究顯示以手術日起算至術後兩年期間衡量,機器人手術病患每位病患的成本約低3,000歐元。作者結論認為,臨床結果的改善帶來術後成本的降低。
In the quarter, there was considerable interest in colorectal clinical data with the initial outcomes reported from the ROLARR study. In addition, several other notable studies were published during the quarter. Let me take a moment to highlight two studies from large-scale, state-wide, general surgery registries published in Surgical Endoscopy.
本季結直腸臨床數據受到高度關注,因為ROLARR研究的初步結果已被報告。此外,本季也發表了其他幾項值得注意的研究。我簡要重點介紹兩項刊登於《Surgical Endoscopy》的大型、全州一般外科登錄資料研究。
The first study was published by Dr. Cleary and team from St. Joseph Mercy Health System in Michigan. After reviewing over 2,700 minimally invasive colorectal surgeries from the Michigan Surgical Quality Collaborative Registry, the authors found that conversion rates were lower with robotic compared to laparoscopic procedures for rectal resections. And hospital length of stay was shorter with robotic procedures compared to conventional and hand-assisted laparoscopic colon procedures.
第一項研究由密西根州St.Joseph Mercy Health System的Cleary醫師及其團隊發表。在回顧密西根外科品質協作登錄(Michigan Surgical Quality Collaborative Registry)中超過2,700例微創結直腸手術後,作者發現,在直腸切除術中,機器人手術相較於腹腔鏡手術的轉開腹率較低。且相較於傳統與手輔式腹腔鏡結腸手術,機器人手術的住院天數更短。
The second study was published by Dr. Altieri and colleagues from Stony Brook University. In a broad-based study of nearly 170,000 minimally invasive general surgeries from the New York Statewide Planning and Research Cooperative System, the authors found that robotic assisted procedures had lower rates of complications and hospital length of stay compared to laparoscopy across several general surgeries, with a lower rate of complications for colectomies.
第二項研究由石溪大學(Stony Brook University)的Altieri醫師及其同事發表。在一項涵蓋紐約州全州規劃與研究合作系統(New York Statewide Planning and Research Cooperative System)中近17萬例微創一般外科手術的廣泛研究中,作者發現,在多項一般外科手術中,機器人輔助手術相較於腹腔鏡手術具有較低的併發症發生率與較短的住院天數;其中結腸切除術的併發症發生率亦較低。
They concluded, quote, robotic approaches may facilitate safer adoption of minimally invasive approaches in areas where penetrance of conventional laparoscopy is low, such as in colorectal surgery, close quote.
他們的結論是,引用原文,機器人手術方式可能有助於在傳統腹腔鏡滲透率較低的領域(例如結直腸手術)更安全地採用微創手術方式,引用結束。
This concludes my procedures and clinical commentary. I will now be providing you with our updated financial outlook for 2015.
以上是我的手術量與臨床評論。接下來我將向各位提供我們更新後的 2015 年財務展望。
Starting with procedures, on our last call we estimated full-year 2015 procedure growth of 8% to 11% above the approximately 570,000 procedures performed in 2014. We are now increasing our procedure estimate for 2015. We now anticipate full-year 2015 procedure growth within a range of 11% to 13%.
先從手術量談起,在上次電話會議中,我們估計 2015 年全年手術量成長將較 2014 年約 57 萬例手術增加 8% 至 11%。我們現在上調 2015 年的手術量估計。我們目前預期 2015 年全年手術量成長區間為 11% 至 13%。
Turning to gross profit, our outlook for gross profit margin has modestly improved compared to last quarter. We expect our second-half 2015 pro forma gross profit margin to be within a range of 67% to 68% of revenue.
再來看毛利,我們對毛利率的展望相較上季略有改善。我們預期 2015 年下半年備考毛利率將落在營收的 67% 至 68% 區間。
Note that this range is a bit lower than our second-quarter gross margin, as Q2 benefited from favorable product and regional system mix, and Q3 and Q4 will likely face stronger foreign exchange headwinds. Our actual gross profit margin will vary quarter-to-quarter, depending largely on product and regional mix, systems production volume, and foreign exchange rates.
請注意,這個區間略低於我們第二季的毛利率,因為第二季受惠於有利的產品與區域系統組合,而第三季與第四季可能面臨更強的外匯逆風。我們的實際毛利率將隨季度波動,主要取決於產品與區域組合、系統生產量,以及外匯匯率。
Turning to operating expenses. Consistent with our last call, we continue to expect to grow pro forma 2015 operating expenses towards the lower end of a range between 7% and 10% above 2014 levels. We now expect our 2015 non-cash stock compensation expense to come in towards the lower end of the $170 million to $180 million range forecast on our last call, fairly flat compared to $169 million in 2014. We expect other income, which is comprised mostly of interest income, to total between $16 million and $18 million in 2015.
接著談營業費用。與上次電話會議一致,我們仍預期 2015 年備考營業費用成長將接近較低端,介於較 2014 年水準增加 7% 至 10% 的區間。我們目前預期 2015 年非現金股票酬勞費用將落在上次電話會議預估的 1.70 億至 1.80 億美元區間的較低端,與 2014 年的 1.69 億美元大致持平。我們預期其他收入(主要由利息收入構成)在 2015 年合計將介於 1,600 萬至 1,800 萬美元。
With regard to income tax, for the remainder of the year we continue to expect our 2015 pro forma income tax rate to be between 28% and 30% of pre-tax income, depending primarily on the mix of US and international profits. This forecast does not assume the reinstatement of the R&D tax credit in 2015.
就所得稅而言,在今年剩餘期間,我們仍預期 2015 年備考有效所得稅率將為稅前所得的 28% 至 30%,主要取決於美國與國際獲利的組合。此預測未假設 2015 年研發(R&D)稅額抵減恢復。
That concludes our prepared comments. We will now open the call to your questions.
以上是我們的準備發言。接下來我們將開放提問。
Operator
Operator
(Operator Instructions). Bob Hopkins, Bank of America.
(接線員指示)。美國銀行(Bank of America)的 Bob Hopkins。
Bob Hopkins - Analyst
Bob Hopkins - Analyst
Congratulations on a good quarter. Wanted to ask two quick questions. First on the gross margin side, I appreciate the specific guidance for the near-term and the back half. But Gary and Marshall, I was wondering if I could just get your views on a little bit longer term. Because gross margin is definitely a major issue for investors as they consider your Company and the stock.
恭喜本季表現不錯。我想快速問兩個問題。第一個關於毛利率,我很感謝你們對短期與下半年提供了具體指引。但 Gary 和 Marshall,我想請教你們對稍長期的看法。因為毛利率對投資人評估你們公司與股票而言,確實是一個重大議題。
So is the back-half level that you're talking about here, 67% to 68%, as you think about the long-term, is that a level that you view as sustainable when you think about all the different puts and takes? Would just love a comment on long-term gross margin. Thank you.
所以你們這裡提到的下半年水準 67% 到 68%,從長期來看,在考量各種拉抬與壓抑因素後,你們認為這個水準可持續嗎?很希望你們能評論一下長期毛利率。謝謝。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
We don't -- as we look at long-term, we don't see huge changes from that range. There are a lot of puts and takes that make it hard to call. So as we get scale on some of the newer products, we get some benefits in terms of cost and cost reduction. There are regional variances, so that as mix changes in regions in terms of regional pricing, there are some things that will make it go up and down.
我們不——從長期來看,我們不認為會與那個區間有很大的變化。有很多拉抬與壓抑因素,使得很難下定論。因此,當我們在一些較新的產品上達到規模時,我們會在成本與降本方面獲得一些效益。也存在區域差異,所以當區域組合在區域定價方面發生變化時,會有一些因素讓毛利率上下波動。
Longer term, we will benefit from some cost advantages. But we also think that, depending on the changes in the marketplace and the scale of some of our customers, there are other pressures. So, we think where we are today, that's a pretty good number to think about.
從更長期來看,我們會受惠於一些成本優勢。但我們也認為,取決於市場變化以及部分客戶的規模,仍會有其他壓力。因此,我們認為以我們目前的水準來看,作為參考是一個相當不錯的數字。
Bob Hopkins - Analyst
Bob Hopkins - Analyst
Okay. And then as a follow-up, two other quick things. You've said a -- it sounds like another good quarter on the hernia side. I was just wondering, now that we're a good, solid couple of quarters in, any kind of commentary from you on -- your views on the sustainability of hernia growth over time, now that you are learning a little bit more.
好的。接著追問,另外兩個小問題。你們提到疝氣(hernia)方面看起來又是一個不錯的季度。我想請教,現在我們已經連續幾個季度表現穩健,隨著你們學到更多,你們對疝氣成長隨時間推移的可持續性有何看法?
And I also just wanted to understand the specifics around your comments on Sp, and when we should be thinking about a formal launch of that as we look forward.
另外我也想了解你們對 Sp 的評論細節,以及展望未來,我們應該何時開始把它視為正式上市(launch)的時間點。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Sure. So on the hernia side, as you mentioned, we're seeing good early growth. But recognize that hernia is both more than one kind of procedure, abdominal hernia or ventral hernia and inguinal hernia. And even within those, there's variation in both technique and patient population.
當然。在疝氣方面,如你所提,我們看到良好的早期成長。但要注意,疝氣不只是一種手術,包含腹壁疝(ventral hernia)與腹股溝疝(inguinal hernia)。即便在這些類別之內,手術技術與病患族群也都有差異。
So, clearly, right now, there's a mixture of sustained use by our customers and people who are learning and trialing the technology. What that mix looks like in the near term is actually very hard to determine. We do see some early evidence of a strong clinical benefit in some of the categories and segments, and we think that's long-term durable.
因此,很明顯地,目前同時存在客戶的持續使用,以及正在學習與試用這項技術的人。短期內這個組合會長什麼樣,其實很難判斷。我們確實在某些類別與區隔看到一些早期證據,顯示有顯著的臨床效益,我們認為那在長期是可持續的。
Calling right now how big those total available markets are going to be is still premature. So we have some basic estimates; we're working them down. As the quarters go by here, we'll be able to increase our certainty of what those long-terms look like.
目前就要判斷那些可服務總市場(TAM)會有多大仍為時過早。所以我們有一些基本估算;也正在把估算範圍逐步收斂。隨著季度推進,我們將能更有把握地判斷那些長期前景會是什麼樣子。
With regard to Sp, we're not predicting the ship date at this time. We're on track in our technical developments. We're in conversations with several surgeon groups as well as regulators about where both long-term value can be and what regulatory pathways are. And as those firm up, we'll share them with you in the future.
至於 Sp,我們目前不預測出貨日期。我們的技術開發進度如期。我們正與多個外科醫師團體以及監管機構討論,長期價值可能在哪裡,以及可行的監管途徑為何。當這些更明確後,我們未來會再與各位分享。
Bob Hopkins - Analyst
Bob Hopkins - Analyst
Great. But that's still a 2016 event, right?
很好。但那仍然是 2016 年的事件,對吧?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
We have not anchored on when we're launching.
我們尚未鎖定何時上市。
Bob Hopkins - Analyst
Bob Hopkins - Analyst
Okay. Thanks for taking the questions.
好的。謝謝回答問題。
Operator
Operator
Tao Levy, Wedbush.
Wedbush 的 Tao Levy。
Tao Levy - Analyst
Tao Levy - Analyst
Maybe the first question, thinking about Japan and next April and reimbursement, I know you mentioned that you submitted some of the kidney data to the regulatory authorities recently. Are there any other clinical data that are either required or that you are going to be submitting between now and reimbursement decision time?
第一個問題,關於日本以及明年四月的給付(reimbursement),我知道你提到你們最近向監管機關提交了一些腎臟的數據。在現在到給付決策時間點之間,是否還有任何其他臨床數據是必須的,或是你們打算提交的?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Yes, so technically, by the way, the submissions are done by the clinical investigators, not by Intuitive. We don't see another clinical data submission between now and April. On the other hand, the pathway that partial nephrectomy went through is something called [sanction euro]. That is not the only pathway to have a conversation with the government.
是的,順帶一提,技術上這些提交是由臨床研究者完成的,而不是由 Intuitive 提交。我們不認為在現在到四月之間還會有其他臨床數據提交。另一方面,部分腎切除術(partial nephrectomy)所走的途徑稱為 [sanction euro]。那並不是與政府對話的唯一途徑。
So, the one data said that we see going in at the time is partial nephrectomy, but there are other conversations ongoing that don't necessarily have the same pathway. And nothing has been assured. We can't anchor you on any particular pathway, but we're having multiple conversations.
因此,我們看到在那個時間點會送進去的一項數據是部分腎切除術,但也有其他正在進行的對話,不一定採用相同的途徑。而且目前沒有任何事情是被保證的。我們無法讓各位以任何特定途徑作為錨定,但我們正在進行多方對話。
Tao Levy - Analyst
Tao Levy - Analyst
Okay, perfect. So just to reiterate that, just because there aren't other studies doesn't mean that you couldn't potentially get reimbursement in other procedures?
好的,完美。所以再重申一次,僅僅因為沒有其他研究,並不代表你在其他手術中就不可能獲得給付報銷,對嗎?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Right. Right, there are other methods besides just this one.
對。對,除了這一種之外,還有其他方法。
Calvin Darling - Director, FP&A and IR
Calvin Darling - Director, FP&A and IR
Yes, we're not anchored on that April 2016 time frame, either. These other methodologies could occur at any time.
是的,我們也不會被錨定在2016年4月那個時間框架上。這些其他方法論可以在任何時間發生。
Tao Levy - Analyst
Tao Levy - Analyst
Okay.
好的。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Having said that, there are uncertain, and they take real work and --.
話雖如此,這些仍有不確定性,而且需要實際投入大量工作,並且——。
Tao Levy - Analyst
Tao Levy - Analyst
I understand that. So, my next question, if you think of the instruments that you've recently gotten approved, some of the more advanced disposables -- whether it's stapling and you've got now on the Xi, the energy -- or I guess you had that last year. But as you think about penetration of the applicable type of procedures where those types of instruments are commonly used laparoscopically, what type of penetration should we be thinking about today?
我理解。那我下一個問題是,若你想想你們最近獲准的器械,一些更進階的一次性耗材——不論是你們現在在Xi上的縫合釘合(stapling)、能量器械——或者我想你們去年就有了。但當你思考在適用的手術類型中,這些器械在腹腔鏡下通常會被使用的滲透率時,我們今天應該怎麼看待這個滲透率?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
So, the stapling products that we have in the market today are primarily focused on colorectal surgery, and we're seeing really nice adoption in that procedure. That's what they were designed for. Staplers are typically used in those procedures, and the adoption of Intuitive's product in that case has been good. So we've been pleased with that.
所以,我們目前在市場上的釘合產品主要聚焦於大腸直腸手術,我們在該手術中看到非常好的採用率。這正是它們被設計用來服務的領域。釘合器通常會用在這些手術中,而在這種情況下,直覺(Intuitive)的產品採用情況一直不錯。所以我們對此很滿意。
Things like vessel sealing are used more broadly. And so we see an increasing penetration of our vessel sealer in a variety of procedures, from general surgery to gynecology and others. So they've been good products for us. I think they're meeting customers' needs, and we've seen growth.
像血管封合(vessel sealing)這類產品的使用範圍更廣。因此我們看到我們的血管封合器在各類手術中的滲透率持續提升,從一般外科到婦科以及其他領域。所以這些對我們來說都是很好的產品。我認為它們滿足了客戶需求,我們也看到了成長。
Tao Levy - Analyst
Tao Levy - Analyst
But in terms of the percent of times that the surgeon would use an assistant port, for example, for a stapler or a sealer while doing a da Vinci procedure, are there any metrics around that that you've looked at?
但就例如外科醫師在進行達文西手術時,會有多少比例的情況會使用助手孔(assistant port),比如用來放釘合器或封合器;你們有看過這方面的任何指標嗎?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
We do track how often they use ours. I don't think we've gotten to a place of disclosing what the breakouts are for each of the sub-units.
我們確實會追蹤他們使用我們產品的頻率。我不認為我們已經到可以披露各個子單元拆分數據的程度。
Tao Levy - Analyst
Tao Levy - Analyst
Okay, great. Thanks a lot.
好的,很棒。非常感謝。
Operator
Operator
Tycho Peterson, JPMorgan.
摩根大通(JPMorgan)的Tycho Peterson。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
Gary, I'm wondering if you can elaborate a little bit on some of the developments for the back half of the year, and in particular around the intraoperable table motion for Xi. Just trying to understand, does this open up more complex procedures? How do you think about the opportunity set? And then similarly with Single-Site for Xi, how do we think about the initial rollout?
Gary,我想請你再多談一點下半年的一些進展,特別是Xi的術中手術台移動(intraoperative table motion)。我想了解的是,這是否會開啟更複雜的手術?你如何看待其機會集合?另外同樣地,Xi的Single-Site,我們該如何看待初期的推廣?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Sure. With regard to table motion, the value of it, why do it -- the value of an integrated intraoperative table is that it allows the surgeon to position the patient using gravity. It is something that they do frequently. It also allows the anesthesiologist easier interaction to help manage the patient. And the power of the integration we've done with our partner has been that it allows it to be done quickly and efficiently, so it's fast.
當然。就手術台移動而言,它的價值、為什麼要做——整合式術中手術台的價值在於,它讓外科醫師可以利用重力來調整病人體位。這是他們很常做的事情。它也讓麻醉科醫師更容易介入互動,以協助管理病人。而我們與合作夥伴所做的整合,其強大之處在於能夠快速且有效率地完成,因此速度很快。
So the real value here is to speed up procedures. It allows them to do it seamlessly. And so we don't think it's so much opening a different market as it is making it easier and lowering barriers.
所以這裡真正的價值是加快手術流程。它讓他們可以無縫地完成。因此我們不認為它是在開啟一個不同的市場,而是讓事情更容易、降低門檻。
The feedback to it, they've been now used in dozens of cases in Europe, where it has CE Mark. Feedback has been really good. And the implementation done by the team is very, very good. So that looks good and we're encouraged. We've submitted the 510(k) just recently, so we'll go answer FDA's questions as they come and work through that.
目前的回饋是,它在歐洲已經用於數十例手術,並已取得CE Mark。回饋非常好。而團隊所做的導入實作也非常、非常到位。所以看起來很不錯,我們也受到鼓舞。我們最近剛提交510(k),接下來會在FDA提出問題時逐一回覆並推進流程。
It really is rounding out -- it's one of the features that rounds out the Xi platform. Intraoperative table motion is a strong beneficiary for general surgery procedures, where folks are wanting to move around the abdomen; helps a lot in that setting. And so the fact that they can do that dynamically is powerful.
它確實是在補齊——它是讓Xi平台更完整的功能之一。術中手術台移動對一般外科手術是很大的受益者,因為大家希望能在腹部不同區域間移動;在那種情境下非常有幫助。因此他們能夠動態地做到這點,威力很大。
Turning to Single-Site on Xi, Single-Site is already available, of course as you know, on the Si. There's nothing that's a technological limitation from putting it on the Xi. It's really been doing the work and getting the clearances.
再談到Xi上的Single-Site,當然如你所知,Single-Site已經可在Si上使用。把它放到Xi上並沒有技術上的限制。主要是把工作做完並取得核准。
What that will enable is the midsized hospital that owns one platform, they may have an Si now; they're doing Single-Site and they want to upgrade to an Xi. That completes the set for them, so they don't have to step away from something on their Si system when they move to Xi. And so that's really the opportunity for us there. And we're meeting our clinical milestones and -- I'm sorry, our technical milestones, and working through the set of validations that will be required to get clearance. So we're excited about it.
這將使得擁有單一平台的中型醫院受益;他們現在可能有一台Si,正在做Single-Site,並希望升級到Xi。這就把他們的配置補齊,讓他們在從Si系統轉到Xi時,不必放棄Si上原本能做的某些事情。所以那就是我們在那裡的機會。而我們正在達成我們的臨床里程碑——抱歉,是技術里程碑,並推進取得核准所需的一系列驗證工作。所以我們很期待。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
All right. And then a question on ROLARR, now that we've seen the data, I'm just wondering how the discussions with surgeons has evolved. Has this opened up some doors for you, potentially showing equivalency with laparoscopic? And yes, just wondering how you are marketing that to your physician base.
好。接著一個關於ROLARR的問題,現在我們已經看到數據了,我想知道你們與外科醫師的討論如何演變。這是否為你們打開了一些門,可能顯示與腹腔鏡具有等效性?以及,你們如何把這點行銷給你們的醫師客群?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
The conversation has generally been positive. As you know, ROLARR is -- really studies a little subgroup. So the trial design is such that it's comparing advanced laparoscopists, highly experienced laparoscopists to new robotic surgeons in rectal cancer. What is not said in that study is that the dominant treatment modality in rectal cancer is open surgery. So to show good data upfront as they presented showing equivalents and leaning towards some potential benefits even in that early stage in the small subgroup that is minimally invasively treated today, I think that's generally been seen as a positive. I don't think it's been ground shaking in either direction, but I think it's generally been well received by our customer base.
整體對話普遍是正面的。如你所知,ROLARR其實——研究的是一個較小的子族群。因此試驗設計是在直腸癌領域,將進階腹腔鏡醫師、非常有經驗的腹腔鏡醫師,與新的機器人外科醫師做比較。該研究沒有提到的是,直腸癌的主流治療方式是開放手術。因此,他們在早期階段所呈現的良好數據,顯示結果等效,甚至在目前僅有少數接受微創治療的子族群中也略偏向一些潛在益處,我認為整體被視為正面。我不認為它在任何方向上都具有顛覆性,但我認為我們的客戶群普遍接受度良好。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
And then just last one going back to the original question on the margins, on Sp in particular, I think part of your reason -- the original delay occurred was to get the engineering right and the manufacturing right.
最後一個問題回到最初關於毛利率的問題,特別是Sp。我想你們當初延後的部分原因——是為了把工程設計與製造端做好。
Are you able to just talk a little bit about how you are thinking about the margin profile of Sp when it comes out? Shouldn't it be additive to the overall base you are talking about?
你能否談談你們如何看待Sp推出時的毛利率輪廓?它不應該對你所談的整體基礎帶來增益嗎?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Yes, as we think about Sp and margins, in total really were looking for those procedures where we can really show significant outcome value. And I think there are some really interesting potentials out there. Sp is a fundamentally different way to deliver the instrumentation relative to multiport. We have some experience in single port with Single-Site, but Sp allows us some different opportunities.
是的,當我們思考Sp與毛利率時,整體而言我們是在尋找那些我們能夠真正展現顯著臨床結果價值的手術。我認為那裡有一些非常有趣的潛力。相較於多孔(multiport),Sp在器械輸送方式上是根本不同的方法。我們在Single-Site上有一些單孔經驗,但Sp讓我們有一些不同的機會。
That said, it's a little more complicated. Now, the engineering side has done a great job. The engineering team in terms of getting both the cost structure and the performance where we want it has been very good. What we want to do is match that up with potential clinical outcomes that really are strong beneficiaries of our approach. That's really what the clinical side of work has been, and I'm feeling positive on it. I think that the design is really enabling.
話雖如此,情況其實更複雜一些。目前工程端做得非常出色。工程團隊在把成本結構與效能調整到我們希望的水準方面表現很好。我們想做的是把這些與潛在的臨床結果對接起來,而這些臨床結果確實會是我們方法的強力受益者。這正是臨床端工作的重點,我對此感到樂觀。我認為這個設計確實具有促成作用。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
Okay, thank you.
好的,謝謝。
Operator
Operator
Ben Andrew, William Blair.
Ben Andrew,William Blair。
Ben Andrew - Analyst
Ben Andrew - Analyst
If you think about the improvement we've seen versus the earlier guidance, primarily coming from gross margin -- and I know, Gary, you guys have been investing aggressively in Europe and overseas for quite some time now. Can we see some of that taper, and see more of the upside flowing through the operating margin over the next year or two?
如果你回頭看相較於先前指引我們看到的改善,主要來自毛利率——而且我知道,Gary,你們在歐洲與海外已經積極投資相當長一段時間了。我們是否會看到這些投資開始趨緩,並在未來一到兩年讓更多上行空間反映到營業利益率上?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
On the time horizon, it depends a lot on which part of the world you are in. I think that -- as we've talked about -- in Japan, we now have a direct team there starting to perform more effectively. I think as they're integrating, that looks really good. There are barriers and other things that have to be overcome structurally. And how quickly those resolve I think will determine the pace of the commercial business, and we've talked about it already; things like reimbursement.
就時間軸而言,很大程度取決於你所在的世界哪個區域。我認為——如同我們談過的——在日本,我們現在有一支直營團隊,開始更有效地發揮作用。我認為隨著他們完成整合,前景看起來相當不錯。但在結構上仍有一些障礙與其他事項需要克服。而這些問題能多快解決,我認為將決定商業業務的推進速度;我們也已經談過,例如給付(reimbursement)等。
In Europe, I think we're seeing a nice performance in several countries. The barriers are a little bit different, depending on which country it is. Not every country is working at the same pace. But we are seeing some of the return on the investments in Europe, and we expect both better performance out of Europe in future quarters, and some continued investment.
在歐洲,我認為我們在數個國家看到不錯的表現。各國的障礙略有不同。並非每個國家的進展速度都一樣。但我們確實看到歐洲投資的一些回報,我們預期未來幾季歐洲的表現會更好,同時也會持續投入部分投資。
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
But I think you were headed towards -- is there additional leverage? And I think that although those are providing return, we'll continuously be investing in overseas markets. As we've characterized before, there's a really large opportunity out there, and we have other things we have to get done.
但我想你真正想問的是——是否還有額外的營運槓桿?我認為,雖然這些投資正在帶來回報,我們仍會持續投資海外市場。如同我們先前所描述的,海外有非常大的機會,而我們也還有其他事情需要完成。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. And then just a quick check-the-box question. The procedure guidance, is that consistent O-US, US, versus what we've seen year-to-date?
好的。接著是一個快速的確認問題。手術量指引在 O-US、US 之間,是否與我們今年迄今看到的情況一致?
Calvin Darling - Director, FP&A and IR
Calvin Darling - Director, FP&A and IR
Yes, I think in the commentary on the call, we talked about the second quarter really being a continuation of the first-quarter trends. And I think that when you talk about the second half of the year, we are talking about a continuation of what we saw in the first half, both domestically and internationally. And the variance in the range really has more to do with just the magnitude of those key drivers that we went through.
是的,我認為在電話會議的說明中,我們提到第二季基本上是第一季趨勢的延續。而當你談到下半年時,我們談的是延續上半年所看到的情況,無論在國內或國際市場皆然。而區間範圍的差異,更多只是取決於我們剛剛提到的那些關鍵驅動因素的幅度大小。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. And then last for me today, please -- Gary, if you think about pocket share or revenue per procedure in usage -- and I know it's potentially variable with Sp, but how does that evolve over a 3- to 5-year window? Because you've got vessel sealing, you've got the stapler; those are relatively underpenetrated versus where they could go. You've been running kind of flattish, even with some erosion in procedure potential, if you will, in the number of instruments. You're running flattish on revenue per case. Where does that go? Are you just hoping to hold it steady? Or do you see a lot of rich targets out there to grab additional pocket share?
好的。最後一題——Gary,如果你從錢包份額(pocket share)或每例手術的使用收入(revenue per procedure)的角度來看——我知道這可能會隨 Sp 而有所變動——在 3 到 5 年的時間窗內會如何演變?因為你們有血管封合,也有吻合器;相較於其潛在空間,這些的滲透率仍偏低。即使在你所謂的手術量潛在侵蝕、也就是器械數量方面有些下滑,你們的表現仍大致持平。每例收入也大致持平。那未來會走向哪裡?你們只是希望維持穩定嗎?還是你們看到很多很有吸引力的目標,可以去爭取更多錢包份額?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I think in the midterm, there will be some trades here of some efficiency gains realized by hospitals and some increased penetration of advanced instrumentation. I think in the longer term, the efficiency gains will find a bottom, and the advanced instrumentation will continue to grow.
我認為在中期,會出現一些取捨:一方面是醫院實現的效率提升,另一方面是先進器械的滲透率提高。我認為在更長期,效率提升會觸底,而先進器械將持續成長。
Calvin Darling - Director, FP&A and IR
Calvin Darling - Director, FP&A and IR
Yes, you look at where Q2 came in terms of revenue per procedure, at the $1,830 level. About what we would've expected, consistent with the last quarter and the last year. But there were some trade-offs. I think foreign exchange hit us harder and we did have some benefit from the newer products that we've talked about that largely offset it. So, a lot of moving parts.
是的,你看第二季每例手術收入落在 1,830 美元的水準。大致符合我們的預期,與上一季以及去年一致。但其中存在一些取捨。我認為外匯對我們的衝擊更大,而我們也確實從我們談過的新產品中獲得一些助益,基本上抵銷了這個影響。所以,變動因素很多。
As we look into the second half, we'd probably assume something similar we've seen in the first half on instrument accessory revenue per procedure. But to offset the exchange, you're probably going to have to have some favorability in other areas.
展望下半年,我們大概會假設器械與配件的每例手術收入,會與上半年看到的情況相近。但要抵銷匯率影響,你可能需要在其他領域出現一些有利因素。
Ben Andrew - Analyst
Ben Andrew - Analyst
Great, thank you.
很好,謝謝。
Operator
Operator
Matt Taylor, Barclays.
Matt Taylor,Barclays。
Matt Taylor - Analyst
Matt Taylor - Analyst
I wanted to ask about some of the drivers here that could lead to system sales. I know you don't give guidance there. But could you talk about the importance of the movable table, the instruments, and those other factors that you've talked about in driving the sales, and whether you may see some sequential uptick over the next couple quarters?
我想問一些可能帶動系統銷售的驅動因素。我知道你們不提供那方面的指引。但你能否談談可移動手術台、器械,以及你們提到的其他因素在推動銷售上的重要性?以及未來幾季是否可能看到逐季回升?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Yes, just speaking to the main levers here of system purchase decisions, there's really three levers that we've talked about and remain in place. One of them is upgrade. For a customer who has a system and is thinking about upgrading from an S or an Si or one of the prior systems, they are really looking out and saying, does Xi bring to them either outcome benefit or new service lines relative to prior products? That's where table motion and Single-Site can make a difference, particularly for single system hospitals. And so we think as those product lines fill out, that will help that upgrade pipeline.
可以。就系統採購決策的主要槓桿而言,基本上有三個槓桿,我們一直在談,而且目前仍然成立。其中之一是升級。對於已經擁有系統、並考慮從 S、Si 或其他先前系統升級的客戶,他們會往前看並問:Xi 相較於先前產品,是否能帶來結果改善或新的服務線?這就是手術台移動與 Single-Site 能產生差異的地方,特別是對於只有一台系統的醫院。因此我們認為,隨著這些產品線逐步完善,將有助於升級管線。
There are people who just buy purely on capacity. They have used the existing capacity of their system; as procedures grow, they look to do additional procedures; they will buy a second system or so.
也有人純粹是基於產能而購買。他們已經用滿現有系統的產能;隨著手術量成長,他們希望做更多手術;因此會再買第二台系統之類的。
And the last one is really capacity again, but often -- is it in the right place? If you are a larger institution or an integrated delivery network, you may be interested in moving the capacity to a different region or a different part of your service network. Sometimes they do that by moving systems; sometimes they do that by buying systems. So capital decisions are really predicated on those three pillars.
最後一個其實也是產能,但常見的問題是——產能是否在正確的位置?如果你是一家大型機構或整合式醫療服務網路(integrated delivery network),你可能有興趣把產能移到不同地區或你服務網路的不同部分。有時他們透過移動系統來做到;有時則透過購買系統來做到。因此資本決策基本上是建立在這三大支柱之上。
Matt Taylor - Analyst
Matt Taylor - Analyst
Great, thanks. And one follow-up. You have a lot of runway here in the general surgery arena. But we've heard other physicians talking about ENT and neuro and cardio. Can you talk about how you are looking beyond even the big opportunities here, and in general to other areas on the horizon?
很好,謝謝。再追問一題。你們在一般外科領域還有很長的成長跑道。但我們也聽到其他醫師談到耳鼻喉科(ENT)、神經外科與心臟科。你能否談談你們如何看待超越這些大型機會之外、以及更廣泛地對未來其他領域的布局?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
We're always out scanning, really from the bottom of your feet to the top of your head, to think about where is current surgery difficult or outcomes suboptimal, and in a place where our kinds of technologies can make a difference.
我們一直在持續掃描,真的可以說是從腳底到頭頂,去思考目前哪些手術很困難、或臨床結果不夠理想,以及在哪些領域我們這類技術能帶來改變。
We are already participating in ENT with our Si product. We think Sp will have some real value to add in the ENT space over time.
我們已經透過我們的 Si 產品參與耳鼻喉(ENT)領域。我們認為 Sp 隨著時間推進,將能在 ENT 領域帶來一些實質的附加價值。
There are other things, of course, in our radars as we go. I think that thoracic surgery is something that's going to matter in the future, and something that our kind of technology can make a difference in, in terms of things like lung cancer, mediastinal cancers, and so on.
當然,隨著我們持續推進,雷達上還有其他事項。我認為胸腔外科是未來會變得重要的一塊,而我們這類技術能在其中產生影響,例如在肺癌、縱膈腫瘤等方面。
And so we're looking at those things. And we have, of course, as you might imagine, other things further out that as we get closer to commercialization we'll talk about.
因此我們正在關注這些事情。而且當然,如你所想像的,還有一些更長期的項目,等我們更接近商業化時會再與大家分享。
Matt Taylor - Analyst
Matt Taylor - Analyst
Great. Thanks for the time.
很好。謝謝你撥冗。
Operator
Operator
David Lewis, Morgan Stanley.
David Lewis,摩根士丹利。
David Lewis - Analyst
David Lewis - Analyst
Gary, just two questions. The first is on procedures. The real improvement this quarter was international procedures, I think got better by 7% or so. Can you give us any additional color on where specifically that procedure growth is happening?
Gary,我有兩個問題。第一個是關於手術量。本季真正的改善來自國際手術量,我認為提升了約 7% 左右。你能否再多提供一些細節,具體而言手術量成長是發生在哪些地區?
And you had made this commentary last years about these reinvestments overseas. It certainly seems that those investments are paying off. So maybe just more color on where those investments are happening, and what specific regions the procedures are strong. And I had a quick follow-up.
另外你去年曾評論過在海外的再投資。看起來這些投資確實正在帶來回報。所以也請再多談談這些投資主要發生在哪裡、哪些特定區域的手術量表現強勁。我還有一個簡短的追問。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Okay. Let me give Calvin the floor to just give a little color on the distribution of procedure growth, and then we'll get back to it.
好的。我先請 Calvin 來說明一下手術量成長的分布情況,然後我們再回到你的問題。
Calvin Darling - Director, FP&A and IR
Calvin Darling - Director, FP&A and IR
Yes. I think it went a little beyond just international. I think on the US side, as I mentioned in the prepared comments, we really had stronger-than-anticipated performance in the more mature procedures in the United States; I think continued strong growth in prostatectomy procedures. And then in gynecology, I think we anticipated somewhat of a pullback relative to Q1 -- or relative to the prior year, with a tougher comp. And really we were able to maintain the same -- similar level in that mature category. So I think those exceeded our expectations, and were part of the reason to raise the guidance.
是的。我認為不只是國際市場。在美國方面,如我在事先準備的評論中提到,我們在美國較成熟的手術類別上表現強於預期;我認為前列腺切除手術量仍持續強勁成長。而在婦科方面,相較於第一季——或相較於去年同期,在基期較高的情況下,我們原本預期會有些回落。但實際上我們得以維持在該成熟類別相同——或相近的水準。因此我認為這些都超出我們的預期,也是我們上調指引的部分原因。
And then, as you say, international was driving it. I think Europe was in general tracking to trends and meeting our performance. The majority of our above-expectation growth was in Asia; as I mentioned, most notably China. We also had a very strong quarter in Korea.
然後如你所說,國際市場是主要驅動因素。我認為歐洲整體上是依循趨勢、並達到我們的表現預期。我們超出預期的成長大多來自亞洲;如我提到的,最顯著的是中國。我們在韓國也有非常強勁的一季。
David Lewis - Analyst
David Lewis - Analyst
And then, Gary, just a question on -- I know you get persistent questions on use of the balance sheet. But you've said historically that one of the drivers for using the balance sheet obviously is valuation, but the other driver really was just business visibility. And certainly as evidenced by this quarter, business visibility has markedly improved.
另外,Gary,我想問一個——我知道你們一直被問到資產負債表的運用。但你們過去曾說,運用資產負債表的驅動因素之一顯然是估值,另一個驅動因素其實是業務能見度。而且從本季表現來看,業務能見度已明顯改善。
So, why not use of cash for buyback? Why was the buyback not bigger last quarter? And how are you thinking about -- what's not a better use your cash than buying back your own stock, just given the improvement in visibility? Thank you.
那為什麼不把現金用於回購?為什麼上季的回購規模不更大?在能見度改善的情況下,你們如何思考——有什麼用途會比回購自家股票更能善用你們的現金?謝謝。
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
David, this is Marshall. We philosophically really haven't changed how we approach decisions around cash and utilization of cash or buybacks. And we do have an intention to return excess cash to shareholders through stock buybacks. But as you know, we've executed those opportunistically, based on market valuations.
David,我是 Marshall。從理念上,我們在現金決策、現金運用或回購方面的做法其實沒有改變。我們確實有意透過股票回購把多餘現金回饋給股東。但如你所知,我們是依市場估值機會性地執行。
The stock market, and our stock specifically, has been volatile over time. And it creates opportunities for us to purchase stock at favorable prices. And, in fact, if you go back over the last 2 1/2 years, we've repurchased more than 2 million shares at an average price of under $420 a share. So we're philosophically aligned with what you just said, and that's how we've executed it.
股市,以及我們的股價本身,長期以來都相當波動。這會為我們創造以有利價格買回股票的機會。事實上,回顧過去 2 年半,我們已以每股平均低於 420 美元的價格回購超過 200 萬股。所以我們在理念上與你剛才所說是一致的,而我們也一直是以這種方式來執行。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
David, you said that visibility has improved. Performance certainly improved this quarter on the -- in terms of the how we manage our business and internally and procedures we have strong visibility; the procedures a little less so. But capital remains highly volatile, and just because of the way capital purchase cycles in different economies work.
David,你提到能見度已改善。本季表現確實改善——就我們如何管理業務、內部管理以及手術量而言,我們有很強的能見度;但對手術量的能見度則稍弱一些。不過資本支出仍然高度波動,主要是因為不同經濟體的資本採購週期運作方式所致。
Operator
Operator
David Roman, Goldman Sachs.
David Roman,高盛。
David Roman - Analyst
David Roman - Analyst
I wanted just to start with maybe Gary -- you are giving us just some reflection about what has transpired over the past four quarters. Because as I look at your business, this quarter really seems to represent a coming together of a lot of the key drivers, whether it's system placements, procedure volumes, global expansion, et cetera. Whereas in the past few quarters we've seen some of these things I think move in your favor, but not all of them.
我想先從 Gary 開始——請你回顧一下過去四個季度發生的情況。因為就我對你們業務的觀察,本季似乎代表許多關鍵驅動因素的匯聚,包括系統裝機、手術量、全球擴張等等。而在過去幾個季度,我們看到其中一些因素對你們有利,但我認為並非全部同時發生。
So is there anything that you saw change in the external environment over the course of the second quarter, or in your own business that really led to a positive coalescence of the key, underlying fundamentals here?
所以,在第二季期間,你是否看到外部環境或你們自身業務有任何變化,真正促成這些關鍵、底層基本面出現正向的匯聚?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I didn't see anything that looked really environmentally driven. As Calvin mentioned earlier, I think moving with market trends tend to be things like prostatectomy and malignant hysterectomy, a little bit more mature, where those are probably more likely indicators of the total market behavior, rather than something specific to Intuitive.
我沒有看到任何看起來是由環境因素驅動的變化。如 Calvin 先前提到,我認為隨市場趨勢變動的,往往是像前列腺切除術與惡性子宮切除術這類較成熟的項目;這些可能更能反映整體市場行為,而不是 Intuitive 特有的因素。
With regard to the major drivers that you've been talking about, really I think we've been working on them, in terms of new product launches, investments in Europe, investments in Asia, developing our team, and working on costs and margins. It's really been, roll up your sleeves and do the hard work.
至於你提到的主要驅動因素,我認為我們一直在推進:新產品上市、在歐洲的投資、在亞洲的投資、團隊建置,以及成本與毛利的改善。這真的就是捲起袖子把苦工做完。
And we've had, as you've said, some of those have come together a little earlier than others. I think one quarter is great. It doesn't make a trend, and our job is to keep doing it.
而且如你所說,其中一些因素比其他因素更早匯聚。我認為一個季度的表現很棒。但它不代表趨勢,而我們的工作是持續把它做好。
David Roman - Analyst
David Roman - Analyst
Okay. And as you think about the go forward from here -- and understandably I think it's clear why you're not giving total revenue guidance. But what are the factors that you think could lead you to a point to conclude that what you're seeing this quarter turns into a trend?
了解。那當你們思考接下來的走向——我也理解為什麼你們不提供總營收指引。但你認為有哪些因素可能會讓你們判斷,本季所看到的情況會轉變成一個趨勢?
I understand results would be one of those things. But if you look at factors that you monitor, are we at turning port where robotic surgery growth is back on track versus some of the challenges you've faced over the past couple of years? Or are there nagging factors that you think still need to be addressed?
我理解結果本身會是其中之一。但如果從你們監控的因素來看,我們是否正處於一個轉折點,使機器人手術的成長回到正軌、相較於你們過去幾年面臨的一些挑戰?或者是否仍有一些令人困擾的因素,你認為還需要被解決?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I think there are always things to be worked on, and we've talked about several of them. I think with regard to visibility and predictability of the financials of the business, I think that's really, as I said before, predominantly predicated on capital.
我認為總是有事情需要持續改進,而我們也談過其中幾項。就業務財務表現的能見度與可預測性而言,我認為這如我之前所說,主要仍取決於資本支出。
I think there are some interesting things going in the market. I do think that market acceptance of robotic surgery is increasing. I think some of the debates of where it adds value are starting to be resolved. We see a different tone in some of the surgical conversations more broadly, and I think that's a real positive. So we feel good about that.
我認為市場上正在發生一些有趣的事情。我確實認為市場對機器人手術的接受度正在提高。我認為關於它在哪些方面能增加價值的一些辯論,正開始得到解決。我們在更廣泛的外科討論中看到不同的語氣,我認為這是非常正面的。因此我們對此感到樂觀。
Having said that, I think that working through reimbursement pathways, working through regulatory pathways, and building really capable organizations takes time. And that's what we're focused on, and that will be the biggest predictor of our long-term performance.
話雖如此,我認為推進報銷途徑、推進監管途徑,以及建立真正有能力的組織都需要時間。這正是我們專注的方向,而這也將是我們長期表現的最大預測因素。
David Roman - Analyst
David Roman - Analyst
And maybe lastly, we've started to hear some discussion in the marketplace about potential competition for robotic surgery. Can you maybe just talk about either, A, what you're seeing; and, B, any actions that you're undertaking to position the business well should any new competitors potentially emerge in the next, call it, I don't know, six, 12, 18 months, et cetera?
最後也許再補充一點,我們開始在市場上聽到一些關於機器人手術潛在競爭的討論。你能否談談,A,你們看到了什麼;以及B,若未來大約六、12、18個月等期間可能出現新的競爭者,你們正在採取哪些行動來讓業務保持良好定位?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
We've been unwavering in our commitment to bringing value to surgery and our belief that we can. And, as such, we have really believed that increased competition is inevitable. It's validating in that it has other people putting their investments where they think it will bring value. And I think that actually increases the presence of robotic surgery in surgical societies and in the industry broadly.
我們對於為手術帶來價值,以及我們能做到這一點的信念,一直堅定不移。因此,我們一直相信競爭加劇是不可避免的。這也具有驗證意義,因為其他人也把投資投入到他們認為能帶來價值的地方。而我認為這實際上提升了機器人手術在外科學會以及整個產業中的能見度。
In terms of our competitive position, clearly we've anticipated the increase in competitors over the years, and we've not been idle during that time. So, we've been thoughtful, and have I think made some investments that will make our position long-term sustainable.
就我們的競爭地位而言,顯然多年來我們已預期競爭者會增加,而我們在這段期間並未閒著。因此,我們一直審慎思考,並且我認為已做出一些投資,將使我們的地位在長期上具備可持續性。
David Roman - Analyst
David Roman - Analyst
Okay. Great. Appreciate all that perspective.
好的。很好。感謝你分享這些觀點。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Thank you. I think we have time for one more question, please.
謝謝。我想我們還有時間再問最後一個問題,請。
Operator
Operator
Rich Newitter, Leerink Partners.
Rich Newitter,Leerink Partners。
Unidentified Participant
Unidentified Participant
Good afternoon, this is Ravi in for Rich. He's on the road today. Thank you for taking the question. Got a question on the Japan sales mix; more Sis than Xis. I understand it's early for the Xi launch, but curious as in terms of what you see it would take -- what you envision that it would take in Japan for Xi to inflect more quickly.
下午好,我是Ravi,代替Rich提問。他今天在外出途中。謝謝讓我提問。我有一個關於日本銷售組合的問題;Si多於Xi。我理解Xi剛上市還早,但想請教就你們所見,在日本要讓Xi更快出現加速拐點——你們認為需要具備哪些條件?
And then another one, staying O-US; I think you made a comment a little bit earlier regarding China, where you see procedure growth rates -- system placement driving growth seems to be a little bit of the opposite of the US, where procedures appear to be driving systems.
然後另一個問題,仍然談美國以外(O-US);我想你稍早對中國有一點評論,你們看到的手術量成長率——系統裝機帶動成長似乎與美國有點相反;在美國看起來是手術量在帶動系統。
At what point does the former turn into the latter? And any sort of -- I mean, are there certain number of systems or penetration that you look at when (technical difficulty) that opportunity? Thank you.
前者在什麼時點會轉變成後者?以及任何——我的意思是,你們是否會看某個系統數量或滲透率,來判斷(技術困難)那個機會?謝謝。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Yes. I'll let Marshall take the first one on Japan, and I'll take the --.
是的。我先請Marshall回答第一個關於日本的問題,我來回答——。
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
Sure. So in Japan what we said was that we had a split of eight Sis and five Xis. Now remember, Xi was just introduced -- or just approved, I should say -- just approved in late March, so you've really had the opportunity to sell it in a three-month cycle. Selling cycles in Japan are much longer than that. In fact, they take multiple quarters to get systems done. That's why you see Sis getting done in the quarter, because the process for which the budget was established by the hospital and the purchase process takes a long time. And so this is just completion of deals that were already in flight months before this. And it will take time for Xi.
好的。所以在日本,我們說的是八台Si、五台Xi的分布。請記得,Xi是剛推出——或者更準確地說——在3月底才剛獲得核准,所以你真正有機會銷售它的時間只有一個三個月的週期。日本的銷售週期遠比這更長。事實上,完成系統銷售需要跨越多個季度。這就是為什麼你會看到本季度完成的是Si,因為醫院預算編列與採購流程需要很長時間。因此這只是完成了在數月前就已在進行中的交易。而Xi還需要時間。
And all of that should be caveated with the point that right now we have one reimbursement in terms of prostatectomy. We're hopeful to get other reimbursements. But until such time that occurs, system purchases are going to be spotty at best.
此外,以上都必須加上一點前提:目前我們只有一項報銷,針對前列腺切除術。我們希望能取得其他報銷。但在那之前,系統採購充其量只會是零星的。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
With regard to China, while we're pleased with the procedure growth and it has been strong, you're absolutely right: in early markets where there aren't a lot of systems placed, then system placements drive procedure growth. And in mature markets, or more mature markets like the United States, where you have more capacity than procedure growth, turns around and drives the systems.
至於中國,雖然我們對手術量成長感到滿意,而且確實很強勁,但你完全說得對:在早期市場、系統裝機量不多時,系統裝機會帶動手術量成長。而在成熟市場或較成熟的市場(例如美國),當系統產能多於手術量成長時,情況就會反過來,由手術量帶動系統。
You were asking, what's the pivot or the inflection point there? It really comes down to accessibility, vis-a-vis the patient population you are trying to treat. So, how many systems are in the neighborhood of the patients who can benefit from them? And so that's really how you have to back into it: start with the patient population that can benefit from them, and work your way backwards into systems.
你問的是,那個轉折點或拐點在哪裡?這其實歸結於可近性(accessibility),相對於你要治療的病患族群而言。也就是說,在能從中受益的病患周邊,有多少台系統可用?因此你必須這樣倒推:先從能受益的病患族群出發,再往回推導需要多少系統。
It's a regional model. We try to do that, but it's not always trivial because of data accessible.
這是一個區域模型。我們嘗試這麼做,但由於可取得的資料限制,並不總是那麼容易。
Well, thank you. That was our last question. As we have said previously, while we focus on financial metrics such as revenues, profits, and cash flow during these conference calls, our organizational focus remains on helping surgeons increase patient value by improving surgical outcomes and reducing surgical trauma.
好的,謝謝。這是我們最後一個問題。如同我們先前所說,雖然我們在這些電話會議中會聚焦於營收、獲利與現金流等財務指標,但我們組織的重點仍是透過改善手術結果並降低手術創傷,來協助外科醫師提升病患價值。
We have built our Company to take surgery beyond the limits of the human hand, and I assure you that we remain committed to driving the vital few things that truly make a difference.
我們打造公司,是為了讓手術超越人手的極限;我向各位保證,我們仍致力於推動那些真正能帶來改變的關鍵少數事項。
This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery. And we look forward to talking to you again in three months.
今天的電話會議到此結束。感謝各位在這段非凡的改善手術旅程中參與並支持我們。我們期待三個月後再與各位交流。